Where G1 Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
G1 Therapeutics (NASDAQ:GTHX) has received 5 bullish and 1 somewhat bullish ratings from analysts in the last quarter, with an average price target of $12.83, representing an upside from the current price of $2.525. This is a 46.54% decrease from the previous average price target of $24.00.
June 26, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
G1 Therapeutics has received positive analyst ratings, with an average price target of $12.83, indicating potential upside from the current price of $2.525.
The positive analyst ratings for G1 Therapeutics indicate that the stock is expected to perform well in the short term. The average price target of $12.83 represents a significant upside from the current price of $2.525, which could attract investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100